Loading clinical trials...
Loading clinical trials...
Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Conditions
Interventions
BHB810
Start Date
June 1, 2026
Primary Completion Date
December 1, 2028
Completion Date
December 1, 2028
Last Updated
April 15, 2026
NCT06340711
NCT06257264
NCT06427941
NCT07537348
NCT06253871
NCT06464978
Lead Sponsor
BigHat Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions